Mary Carrington Selected Research

HLA-B Antigens (HLA-B)

11/2021	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults.
1/2020	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study.
1/2020	The Interaction of LILRB2 with HLA-B Is Associated with Psoriasis Susceptibility.
11/2019	Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon.
1/2018	Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B27:05- and -B27:02-Mediated Control of HIV-1 Infection.
11/2017	HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
6/2014	Distinct assembly profiles of HLA-B molecules.
11/2013	Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection.
10/2013	Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.
11/2012	HIV control through a single nucleotide on the HLA-B locus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Carrington Research Topics

Disease

66	Infections 01/2022 - 05/2002
22	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 01/2002
20	Disease Progression 01/2019 - 10/2006
18	Viremia 01/2022 - 09/2006
15	HIV Infections (HIV Infection) 12/2019 - 05/2006
14	Neoplasms (Cancer) 02/2022 - 04/2002
9	Virus Diseases (Viral Diseases) 01/2017 - 08/2002
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 06/2007
4	COVID-19 01/2022 - 01/2021
4	Communicable Diseases (Infectious Diseases) 12/2021 - 01/2003
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2014 - 11/2007
3	Nasopharyngeal Carcinoma 01/2012 - 11/2005
3	Myositis (Idiopathic Inflammatory Myopathies) 11/2006 - 11/2005
2	Hepatitis C 01/2022 - 06/2009
2	Disease Susceptibility (Diathesis) 11/2021 - 04/2015
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 02/2012
2	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2019 - 02/2016
2	Persistent Infection 01/2018 - 06/2012
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 06/2010
2	Hypersensitivity (Allergy) 01/2017 - 03/2011
2	Crohn Disease (Crohn's Disease) 12/2013 - 04/2013
2	Chronic Hepatitis B 06/2012 - 11/2003
2	Hepatitis B 06/2012 - 12/2008
2	Polymyositis 11/2006 - 11/2005
2	Dermatomyositis (Dermatopolymyositis) 11/2006 - 11/2005
2	Psoriatic Arthritis 10/2004 - 09/2002
1	Melanoma (Melanoma, Malignant) 02/2022
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Parasitemia 01/2021
1	Inflammation (Inflammations) 10/2020
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2020
1	Falciparum Malaria (Plasmodium falciparum Malaria) 12/2017
1	Malaria 12/2017

Drug/Important Bio-Agent (IBA)

26	HLA-B Antigens (HLA-B)IBA 11/2021 - 08/2002
22	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2002
21	LigandsIBA 01/2022 - 05/2002
16	EpitopesIBA 04/2021 - 10/2006
16	HLA-C Antigens (HLA-C)IBA 01/2021 - 09/2002
14	Peptides (Polypeptides)IBA 01/2022 - 11/2005
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
10	VaccinesIBA 01/2022 - 05/2008
10	KIR ReceptorsIBA 01/2021 - 04/2005
9	HLA-A Antigens (HLA-A)IBA 01/2022 - 10/2004
9	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2002
9	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2007
6	InterferonsIBA 01/2022 - 09/2006
6	AntigensIBA 01/2021 - 05/2006
6	Immunoglobulins (Immunoglobulin)IBA 02/2016 - 05/2002
5	Natural Killer Cell ReceptorsIBA 01/2022 - 08/2004
5	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 01/2014
4	HLA-B57 antigenIBA 01/2018 - 02/2011
4	Biological ProductsIBA 02/2015 - 01/2008
3	Pharmaceutical PreparationsIBA 01/2022 - 10/2008
3	Amino Acids FDA Link 01/2022 - 12/2010
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2004
3	HLA-DP Antigens (HLA-DP)IBA 01/2020 - 06/2012
3	HLA-DPB1 antigen (HLA DPB1)IBA 01/2020 - 06/2012
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 10/2006
3	Messenger RNA (mRNA)IBA 01/2016 - 07/2010
3	Interferon-gamma (Interferon, gamma)IBA 11/2014 - 06/2012
3	HLA-DRB1 Chains (HLA DRB1)IBA 07/2013 - 03/2006
3	CytokinesIBA 09/2012 - 08/2002
3	ChemokinesIBA 11/2010 - 05/2009
3	Chemokine ReceptorsIBA 01/2007 - 01/2002
2	tapasinIBA 11/2020 - 06/2014
2	Broadly Neutralizing AntibodiesIBA 12/2019 - 12/2015
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017 - 06/2012
2	MicroRNAs (MicroRNA)IBA 12/2016 - 01/2014
2	EnzymesIBA 11/2014 - 11/2014
2	Codon (Codons)IBA 08/2014 - 08/2009
2	3' Untranslated Regions (3' UTR)IBA 12/2013 - 06/2012
2	HLA-DRB1*03:01 antigenIBA 07/2013 - 11/2006
2	Histocompatibility Antigens Class IIBA 01/2012 - 03/2007
2	HLA-Bw4 antigenIBA 06/2011 - 08/2007
2	Antigen Receptors (Antigen Receptor)IBA 05/2009 - 05/2009
2	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 11/2007 - 12/2004
2	C-Type Lectins (C-Type Lectin)IBA 11/2007 - 12/2004
2	Isoleucine (L-Isoleucine)FDA Link 08/2007 - 08/2002
2	AutoantibodiesIBA 11/2006 - 03/2006
1	DiamondIBA 02/2022
1	NivolumabIBA 01/2022
1	Everolimus FDA Link 01/2022
1	Sunitinib (Sutent)FDA Link 01/2022
1	avelumabIBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Integrase InhibitorsIBA 01/2021
1	IntegrasesIBA 10/2020
1	Fc Receptors (Fc Receptor)IBA 12/2019
1	Long Noncoding RNAIBA 01/2019
1	CCR5 Receptors (CCR5 Receptor)IBA 01/2019

Therapy/Procedure

12	Therapeutics 02/2022 - 10/2007
5	Transplantation 01/2022 - 12/2014
3	Cell Transplantation 01/2020 - 01/2020
2	Aftercare (After-Treatment) 02/2022 - 01/2022
2	Highly Active Antiretroviral Therapy (HAART) 10/2011 - 09/2006
1	Stem Cell Transplantation 01/2022
1	Precision Medicine 12/2021